- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Immunotherapy and Radiation Therapy in cSCC and BCC
Experts explore the optimal sequencing of immunotherapy relative to radiation therapy in CSCC and BCC care.
EP: 1.Prevalence of Cutaneous Squamous Cell Carcinoma (CSCC) & Basal Cell Carcinoma (BCC)
EP: 2.Immunotherapy Landscape in cSCC and BCC
EP: 3.Immunotherapy and Radiation Therapy in cSCC and BCC
EP: 4.Immunotherapy Barriers: Multidisciplinary Approach in cSCC and BCC
EP: 5.Coordination of Care: Interdisciplinary Immunotherapy Challenges in Nonmelanoma Skin Cancers
EP: 6.Multidisciplinary Collaboration: Best Practices for CSCC and BCC Management
EP: 7.Dermatologists and Immunotherapy: Managing Patient Expectations
EP: 8.Monitoring Immunotherapy Toxicities in CSCC and BCC
EP: 9.Staging Disease and Risk Stratification in CSCC and BCC
EP: 10.Targeted Therapy: Hedgehog Inhibitors in BCC
EP: 11.Socioeconomic Implications of CSCC and BCC
EP: 12.Immunosuppression in CSCC and BCC Treatment
EP: 13.Updates in Therapeutics for Nonmelanoma Skin Cancers
EP: 14.Concluding Thoughts on the Future of CSCC and BCC Care
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
Barker explained that immunotherapy is currently FDA-approved and standard of care for advanced cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) when surgery or radiation are no longer options. He stated radiation is sometimes used to palliate symptoms in immunotherapy nonresponders. Regarding integration with curative-intent radiation, he noted that in cSCC, immunotherapy is being studied adjuvant to surgery and radiation, not concurrently, based on success in this sequencing for non–small cell lung and gastroesophageal cancers. He contrasted this with failed trials combining immunotherapy and definitive chemoradiation for head and neck squamous cell carcinoma and other diseases. However, Barker suggested neoadjuvant immunotherapy prior to intense, definitive radiation could be explored in unresectable cSCC. Luke questioned whether smaller radiotherapy fields in skin cancer may better enable combinations with immunotherapy. Barker agreed that in advanced cSCC with both palliative and systemic therapy indications, concurrent radiation and immunotherapy out of clinical necessity may be reasonable.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
